Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Public ClinicalTrials.gov record NCT02077166. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter Open-Label Phase 1b/2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 1b/2 study is designed to assess the safety and efficacy of ibrutinib in combination with lenalidomide and rituximab in subjects with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for transplant.
Study identification
- NCT ID
- NCT02077166
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 138 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 13, 2014 (Actual)
- Primary completion
- Dec 17, 2020 (Actual)
- Completion
- Dec 17, 2020 (Actual)
- Last update posted
- Feb 4, 2022
2014 – 2020
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | 35294 | — |
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Cedar Sinai Medical Center | Los Angeles | California | 90048 | — |
| UCLA Medical Center | Los Angeles | California | 90095 | — |
| University of Florida | Gainesville | Florida | 32610 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| Tulane Medical Center | New Orleans | Louisiana | 70112 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Comprehensive Cancer Center of Nevada | Las Vegas | Nevada | 89169 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Summit Medical Group | Morristown | New Jersey | 07960 | — |
| Weill Cornell Medical Center | New York | New York | 10065 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| University of Cincinnati Health Barrett Center | Cincinnati | Ohio | 45267 | — |
| Mid-Ohio Oncology/ Hematology | Columbus | Ohio | 43219 | — |
| University of TN Medical Center | Knoxville | Tennessee | 37920 | — |
| Vanderbilt Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| Baylor Charles Sammons Cancer Center | Dallas | Texas | 75246 | — |
| The University of Texas, MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Medical Oncology Associates, PS | Spokane | Washington | 99208 | — |
| Northwest Medical Specialities, PLLC | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02077166, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 4, 2022 · Synced Nov 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02077166 live on ClinicalTrials.gov.